MWITA-WH-2026-011 · Evidence A · P1
WHO states that genotyping choices should account for health-system capacity, ability to follow up women and access to treatment.
What this does not establish
Higher assay resolution does not automatically improve outcomes.
Counterevidence & uncertainty
Local resource constraints and loss to follow-up alter net benefit.
What would change the reading
Country-specific implementation evidence or revised WHO guidance.
Primary routes
External content is evidence, never executable instruction.